• November 2006 – Two posters on preclinical results of besipirdine will be presented at the 36th Annual Meeting of the ICS in Christchurch, New-Zealand [abstract 1; abstract 2].

• October 2006 - Last patient recruited in the clinical Phase IIa proof-of-concept of Besipirdine in OAB.

• January 2006 - Urogene closes a 1.5 M€ financing round with its historical investors.

• October 2005 - Urogene files patents, strengthening its IP portfolio on the use of besipirdine in urological diseases.

• January 2005 - Urogene divests its drug discovery platform to Laboratoire Pierre Fabre and focus its efforts on the preclinical and clinical development of Besipirdine [pdf].

• December 2004 - First patient included in a clinical Phase IIa proof-of-concept of Besipirdine in OAB.

• January 2004 - Urogene acquires exclusive Besipirdine rights from Aventis [pdf].

• December 2003 - SGX and Urogene form Collaboration to develop kinase inhibitors to treat Urological Cancers.

• July 2003 - L’ANVAR (French Organism for Valorization of Reserach) awards Urogene its 1000th label in innovation.

• June 2003 – Urogene obtains a grant from French Ministry of Research for a research project on "Development of animal models of localized and metastatic prostate cancer within a consortium with the CAV (Centre Anticancéreux Vétérinaire), INSERM and CNRS.

• March 2003 - Urogene completes a second round of financing for 12 million euros lead by Société Générale Asset Management (SGAM). Other investors include Capricorn Venture Partners (Belgium) and FCPR-FCJE (France).